Shao Jun-Jun, Wong Chung Kai, Lin Tong, Lee Shuk Kwan, Cong Guo-Zheng, Sin Fion Wai Yee, Du Jun-Zheng, Gao Shan-Dian, Liu Xiang-Tao, Cai Xue-Peng, Xie Yong, Chang Hui-Yun, Liu Ji-Xing
Key Laboratory of Animal Virology, Ministry of Agriculture, State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 730046 Lanzhou, China.
Clin Vaccine Immunol. 2011 Jan;18(1):143-9. doi: 10.1128/CVI.00236-10. Epub 2010 Nov 17.
In order to develop a completely safe immunogen to replace the traditional inactivated vaccine, a tandem-repeat multiple-epitope recombinant vaccine against foot-and-mouth disease (FMD) virus (FMDV) type O was developed. It contained three copies each of residues 141 to 160 and 200 to 213 of VP1 of the O/China/99 strain of FMDV coupled with a swine immunoglobulin G heavy-chain constant region (scIgG). The data showed that the multiple-epitope recombinant vaccine elicited high titers of anti-FMDV specific antibodies in swine at 30 days postvaccination (dpv) and conferred complete protection against a challenge with 10³ 50% swine infective doses of the O/China/99 strain. The anti-FMDV specific antibody titers were not significantly different between the multiple-epitope recombinant vaccine and the traditional vaccine (t test, P > 0.05). The number of 50% pig protective doses was 6.47, which is higher than the number recommended by the World Organization for Animal Health. The multiple-epitope recombinant vaccine resulted in a duration of immunity of at least 6 months. We speculate that the multiple-epitope recombinant vaccine is a promising vaccine that may replace the traditional inactivated vaccine for the prevention and control of FMD in swine in the future.
为了研发一种完全安全的免疫原以替代传统的灭活疫苗，研制了一种针对O型口蹄疫病毒（FMDV）的串联重复多表位重组疫苗。它包含FMDV O/China/99株VP1的141至160位残基和200至213位残基各三个拷贝，并与猪免疫球蛋白G重链恒定区（scIgG）偶联。数据显示，多表位重组疫苗在接种后30天（dpv）时能在猪体内诱导出高滴度的抗FMDV特异性抗体，并对10³ 50%猪感染剂量的O/China/99株病毒攻击提供完全保护。多表位重组疫苗与传统疫苗之间的抗FMDV特异性抗体滴度无显著差异（t检验，P>0.05）。50%猪保护剂量数为6.47，高于世界动物卫生组织推荐的数量。多表位重组疫苗的免疫持续时间至少为6个月。我们推测，多表位重组疫苗是一种有前景的疫苗，未来可能替代传统的灭活疫苗用于猪口蹄疫的防控。
